Spots Global Cancer Trial Database for adenocarcinoma of lung
Every month we try and update this database with for adenocarcinoma of lung cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Detection of EGFR Mutations in Liquid Based Cytology Samples | NCT04086680 | Adenocarcinoma ... | 18 Years - 100 Years | Royal Cornwall Hospitals Trust | ||
| Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | NCT04557449 | Liposarcoma CRC Prostate Cancer Breast Neoplasm... Adenocarcinoma ... Solid Tumors | PF-07220060 Letrozole Fulvestrant Midazolam Enzalutamide | 18 Years - | Pfizer | |
| Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies | NCT02485119 | Neoplasms | BAY94-9343 | 20 Years - | Bayer | |
| SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | NCT01362790 | Mesothelioma Adenocarcinoma ... Pancreatic Neop... | Pentostatin Cyclophosphamid... SS1(dsFv)PE38 -... SS1(dsFv)PE38 -... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs | NCT05292859 | Gynecologic Can... Colorectal Canc... Pancreatic Canc... Non-small Cell ... Cholangiocarcin... Ovarian Cancer Ovary Neoplasm Squamous Cell L... Adenocarcinoma ... Adenosquamous C... | Neoantigen spec... | 18 Years - | Alaunos Therapeutics | |
| Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011) | NCT05252676 | Adenocarcinoma ... | 18 Years - | Fudan University | ||
| Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC | NCT03184571 | Lung Cancer Met... NSCLC Stage IV Adenocarcinoma ... | Bemcentinib; pe... | 18 Years - | BerGenBio ASA | |
| To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer | NCT03676192 | Adenocarcinoma ... | CT-16 Avastin | 18 Years - | Celltrion | |
| APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch | NCT05550961 | NSCLC Cancer Lung Cancer Adenocarcinoma ... Squamous Cell L... | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | ||
| Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis | NCT04692935 | Adenocarcinoma ... | 18 Years - 85 Years | Peking University People's Hospital | ||
| ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas | NCT05079022 | Adenocarcinoma ... | Furmonertinib | 18 Years - | Peking University People's Hospital | |
| To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer | NCT03676192 | Adenocarcinoma ... | CT-16 Avastin | 18 Years - | Celltrion | |
| SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | NCT01362790 | Mesothelioma Adenocarcinoma ... Pancreatic Neop... | Pentostatin Cyclophosphamid... SS1(dsFv)PE38 -... SS1(dsFv)PE38 -... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | NCT05456256 | Adenocarcinoma ... Carcinoma, Non-... | LP-300 Pemetrexed Carboplatin | 18 Years - | Lantern Pharma Inc. | |
| Multi-omics Analysis to Characterize the Invasive Evolution of Pulmonary Subsolid Nodules | NCT06215885 | Adenocarcinoma ... | Mass spectromet... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Vaccine Treatment for Advanced Non-Small Cell Lung Cancer | NCT00073398 | Non-small Cell ... Adenocarcinoma ... Squamous Cell C... Large Cell Carc... Lung Neoplasms | Drug: Hyperacut... | 21 Years - 65 Years | Lumos Pharma | |
| ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas | NCT05079022 | Adenocarcinoma ... | Furmonertinib | 18 Years - | Peking University People's Hospital | |
| An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors | NCT02616211 | Adenocarcinoma ... Lung Neoplasm Cancer of Lung Lung Cancer Pulmonary Cance... EGFR Genes ALK Genes | 18 Years - | Mayo Clinic | ||
| Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC | NCT03184571 | Lung Cancer Met... NSCLC Stage IV Adenocarcinoma ... | Bemcentinib; pe... | 18 Years - | BerGenBio ASA | |
| The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR | NCT02493582 | Adenocarcinoma ... | Cytokine-Induce... Apatinib | 18 Years - 70 Years | The First People's Hospital of Changzhou | |
| Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer | NCT05665504 | Lung; Node Adenocarcinoma ... | DetermaRX | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung | NCT03371381 | Adenocarcinoma ... | JNJ-64041757 Nivolumab | 18 Years - | Janssen Research & Development, LLC | |
| ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas | NCT05079022 | Adenocarcinoma ... | Furmonertinib | 18 Years - | Peking University People's Hospital | |
| Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | NCT04557449 | Liposarcoma CRC Prostate Cancer Breast Neoplasm... Adenocarcinoma ... Solid Tumors | PF-07220060 Letrozole Fulvestrant Midazolam Enzalutamide | 18 Years - | Pfizer | |
| The Detection of EGFR Mutations in Liquid Based Cytology Samples | NCT04086680 | Adenocarcinoma ... | 18 Years - 100 Years | Royal Cornwall Hospitals Trust | ||
| Prognostic Value of Lung Cancer MicroAnatomy in 3D | NCT05565677 | Lung Cancer Adenocarcinoma ... Pathology Micro-computed ... X-ray Histology Digital Patholo... | micro-computed ... | 18 Years - | Aristotle University Of Thessaloniki | |
| The Tracking Molecular Evolution for NSCLC (T-MENC) Study | NCT03838588 | Lung Neoplasms Lung Cancer Nonsmall Cell L... Adenocarcinoma ... | 18 Years - 80 Years | Geneplus-Beijing Co. Ltd. | ||
| APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch | NCT05550961 | NSCLC Cancer Lung Cancer Adenocarcinoma ... Squamous Cell L... | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | ||
| LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT04027946 | Lung Cancer Non-Small Cell ... Adenocarcinoma ... | LMB-100 pembrolizumab Mesothelin Expr... TrueSight Oncol... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib | NCT04770688 | Non-Small Cell ... Locally Advance... Metastatic Canc... Adenocarcinoma ... | Osimertinib Anlotinib | 18 Years - | Shanghai Chest Hospital | |
| Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | NCT05194735 | Gynecologic Can... Colorectal Canc... Pancreatic Canc... Non-small Cell ... Cholangiocarcin... Ovarian Cancer Endometrial Can... Ovarian Carcino... Ovary Neoplasm Squamous Cell L... Adenocarcinoma ... Adenosquamous C... | Neoantigen spec... Aldesleukin (IL... | 18 Years - | Alaunos Therapeutics | |
| RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial | NCT04105270 | Adenocarcinoma ... Lung Cancer | Oral Restorativ... Durvalumab 1500... Cisplatin/pemet... Placebo | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| HRCT in Prediction of Tumor Invasion in GGO Lung Adenocarcinoma (ECTOP-1008) | NCT04165759 | Adenocarcinoma ... | 15 Years - 85 Years | Fudan University | ||
| Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma | NCT03361319 | NSCLC, Recurren... Adenocarcinoma ... | Vargatef Abraxane placebo | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis | NCT04692935 | Adenocarcinoma ... | 18 Years - 85 Years | Peking University People's Hospital | ||
| A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma | NCT05764954 | Adenocarcinoma ... | NovoTTF-200T Sy... | 22 Years - | Memorial Sloan Kettering Cancer Center | |
| CISH Inactivated TILs in the Treatment of NSCLC | NCT05566223 | Carcinoma, Non-... Metastatic Non ... Stage IV Non-sm... Squamous Cell L... Adenocarcinoma ... Large Cell Lung... | Fludarabine Cyclophosphamid... CISH Inactivate... Aldesleukin Pembrolizumab | 18 Years - 75 Years | Intima Bioscience, Inc. | |
| Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma | NCT03361319 | NSCLC, Recurren... Adenocarcinoma ... | Vargatef Abraxane placebo | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients | NCT04566432 | Lung Neoplasms Lung Cancer, No... Adenocarcinoma ... Squamous Cell L... | Observation | 18 Years - | Geneplus-Beijing Co. Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
